clinical trial · NCT07535606
A Study to Evaluate ALN-4915 in Adult Healthy Volunteers
Healthy VolunteersALN-4915Placebo
brief summary
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of ALN-4915.
started
Mar 2, 2026
primary completion
Jul 31, 2027
completion
Jul 31, 2027
last updated
Sep 16, 2026
official title
A Phase 1, Randomized, Double-Masked, Placebo-controlled, Single Ascending Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALN-4915 in Adult Healthy Volunteers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol